Patent intelligence · US
US 12291557
Chimeric TIM4 receptors and uses thereof
Chimeric TIM4 receptors and uses thereof
Patent details — US 12291557
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 6, 2025
- Expiration
- May 1, 2045
- Applicant
- Cero Therapeutics Holdings, Inc.
- Claims
- 11
- CPC classes
- A61K, A61K40/11, A61K40/31, A61K40/32
Quick answer
US 12291557 (Chimeric TIM4 receptors and uses thereof) is held by Cero Therapeutics Holdings, Inc.. Status: granted. Granted May 6, 2025. Expires May 1, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cero Therapeutics Holdings, Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K40/11, A61K40/31, A61K40/32, A61K40/4257, A61K45/06
More from Cero Therapeutics Holdings, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12303551
Cellular immunotherapy compositions and uses thereof
granted -
US 11708423
Chimeric engulfment receptor molecules and methods of use
granted -
US 11697689
Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs
granted -
US 11655282
Chimeric engulfment receptor molecules
granted -
US 10675246
Orally administrable compositions comprising calcium
granted -
US 10307410
Mcl-1 modulating compounds for cancer treatment
granted -
US 10273307
Humanized anti-CD134 (OX40) antibodies and uses thereof
granted
Frequently asked questions
What is US patent 12291557?
US 12291557 (Chimeric TIM4 receptors and uses thereof) is held by Cero Therapeutics Holdings, Inc.. Status: granted. Granted May 6, 2025. Expires May 1, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12291557?
Cero Therapeutics Holdings, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 12291557 expire?
Our index shows an expiration date of May 1, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.